data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
InflaRx
(NASDAQ:IFRX)
0.781
-0.399[-33.81%]
At close: Jun 24
1.05
0.269[34.44%]
After Hours: 7:49PM EDT
Day High/Low0.78 - 1.32
52 Week High/Low0.78 - 5.69
Open / Close1.18 / 0.78
Float / Outstanding39.8M / 44.2M
Vol / Avg.767.6K / 170.3K
Mkt Cap34.5M
P/E-
50d Avg. Price1.49
Div / Yield-
Payout Ratio-
EPS-0.32
Total Float39.8M

InflaRx (NASDAQ:IFRX), Quotes and News Summary

InflaRx (NASDAQ: IFRX)

Day High/Low0.78 - 1.32
52 Week High/Low0.78 - 5.69
Open / Close1.18 / 0.78
Float / Outstanding39.8M / 44.2M
Vol / Avg.767.6K / 170.3K
Mkt Cap34.5M
P/E-
50d Avg. Price1.49
Div / Yield-
Payout Ratio-
EPS-0.32
Total Float39.8M
Benzinga - May 13, 2022, 1:55PM
Benzinga - May 13, 2022, 7:09AM
Benzinga - May 13, 2022, 6:57AM
Benzinga - May 13, 2022, 6:43AM
Benzinga - May 12, 2022, 11:15AM
Benzinga - May 12, 2022, 7:36AM
Benzinga - Mar 31, 2022, 2:41PM
Benzinga - Mar 31, 2022, 1:18PM
Benzinga - Mar 31, 2022, 8:00AM
Benzinga - Mar 31, 2022, 7:38AM
Benzinga - Mar 31, 2022, 7:26AM
Benzinga - Mar 25, 2022, 6:02AM
Benzinga - Mar 17, 2022, 10:03AM
Benzinga - Mar 17, 2022, 7:33AM
Benzinga - Feb 28, 2022, 12:10PM
Benzinga - Feb 28, 2022, 11:36AM
Benzinga - Feb 28, 2022, 7:40AM
Benzinga - Feb 16, 2022, 7:31AM
Benzinga - Jan 10, 2022, 7:50AM
Benzinga - Jan 5, 2022, 7:31AM
Benzinga - Nov 23, 2021, 3:37PM
Benzinga - Nov 15, 2021, 3:39PM
Benzinga - Nov 15, 2021, 8:00AM
load more
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-04
REV
Q1 2022Est.ActualSurprise
EPS-0.340-0.360 -0.0200
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

InflaRx Questions & Answers

Q
How do I buy InflaRx (IFRX) stock?
A

You can purchase shares of InflaRx (NASDAQ: IFRX) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are InflaRx's (IFRX) competitors?
A

There are no as such competitors for InflaRx.

Q
What is the target price for InflaRx (IFRX) stock?
A

The latest price target for InflaRx (NASDAQ: IFRX) was reported by Credit Suisse on Friday, May 13, 2022. The analyst firm set a price target for 2.00 expecting IFRX to rise to within 12 months (a possible 156.08% upside). 9 analyst firms have reported ratings in the last year.

Q
Current Stock Price for InflaRx (IFRX)?
A

The stock price for InflaRx (NASDAQ: IFRX) is $0.781 last updated June 24, 2022, 8:00 PM UTC.

Q
Does InflaRx (IFRX) pay a dividend?
A

There are no upcoming dividends for InflaRx.

Q
When is InflaRx (NASDAQ:IFRX) reporting earnings?
A

InflaRx’s Q2 earnings are confirmed for Thursday, August 4, 2022.

Q
Is InflaRx (IFRX) going to split?
A

There is no upcoming split for InflaRx.

Q
What sector and industry does InflaRx (IFRX) operate in?
A

InflaRx is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.